Kabir Hussain
MedImmune, UK
Title: Immunoassays in drug development – Comparing and contrasting different platforms
Biography
Biography: Kabir Hussain
Abstract
The drug development process requires sensitive and robust assays to enable PK/PD and Immunogenicity assessment of biologics. Immunoassays are commonly employed to this purpose, utilising the target-specific properties of antibodies to detect the analyte of interest. With the rapid advances in technology, the range of immunoassay platforms available is growing whilst existing platforms are becoming more refined, enabling bioanalytical scientists to choose a platform that is tailored to their needs. Various factors can influence the choice of platform, these can be either assay related such as sensitivity or assay type (quantitative/immunogenicity), or more general factors such as time and cost effectiveness. The Meso Scale Discovery® platform has become established as a reliable platform, particularly for immunogenicity assessment whereby a homogenous solution phase incubation of the sample with the capture and detection reagents provides a simple, easy to perform assay. The GyrolabTM is a largely automated platform that provides a time effective option allowing quick turnaround for analysis of samples. The CiraTM immunoassay platform from Aushon Biosystems, Inc. provides highly sensitive assays that are ideal for Biomarker analysis and also specialises in multiplexing capabilities, making it an attractive option for pharmacodynamics assessment. Carefully selecting the appropriate platform can improve the likelihood of successfully navigating biologics through the drug development process.